Top Markets
#1 Nesa Nesa +775.61%
#2 Cortex Cortex +68.81%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.79%
#4 QuantixAI QuantixAI +32.58%
#5 EXOD EXOD +22.78%
#6 Pons Pons +22.47%
#7 Venom Venom +11.06%
#8 Renzo Restaked LST Renzo Restaked LST +10.31%
#9 Movement Movement +10.08%
#10 Fartcoin Fartcoin +9.75%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Aardvark Therapeutics, Inc. Common Stock Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock

AARD
Kedudukan dalam Saham #19548
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical... Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Harga Saham
$7.22
Disegerakkan terakhir: 2026-08-25
Modal Pasaran
$158.03M
Perubahan (1 hari)
4.96%
Perubahan (1 tahun)
-24.22%
Negara
US
Perdagangan Aardvark Therapeutics, Inc. Common Stock (AARD)

Kategori

Healthcare
Nisbah P/E bagi Aardvark Therapeutics, Inc. Common Stock (AARD)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Aardvark Therapeutics, Inc. Common Stock, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Aardvark Therapeutics, Inc. Common Stock dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.